Previous Close | 9.00 |
Open | 9.00 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 50.00 |
Expire Date | 2024-06-21 |
Day's Range | 9.00 - 9.00 |
Contract Range | N/A |
Volume | |
Open Interest | 4 |
– Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral presentation – – Additional data and analyses from Phase 3 DeFi trial of OGSIVEO® (nirogacestat) highlighting consistent safety and efficacy across subgroups of adults with desmoid tumors also being presented in oral and poster sessions – STAMFORD, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference, taking place in Las Vegas, Nevada on Tuesday, May 14, 2024 at 3:40 p.m. PT / 6:40 p.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media s
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...